Indications And Dose
To rhesus-negative woman for prevention of Rh0(D) sensitisation, following birth of rhesus-positive infant ▶BY DEEP INTRAMUSCULAR INJECTION ▶Females of childbearing potential: 500 units, dose to be administered immediately or within 72 hours; for transplacental bleed of over 4 mL fetal red cells, extra 100–125 units per mL fetal red cells, subcutaneous route used for patients with bleeding disorders To rhesus-negative woman for prevention of Rh0(D) sensitisation, following any potentially sensitising episode (e.g. stillbirth, abortion, amniocentesis) up to 20 weeks’ gestation ▶BY DEEP INTRAMUSCULAR INJECTION ▶Females of childbearing potential: 250 units per episode, dose to be administered immediately or within 72 hours, subcutaneous route used for patients with bleeding disorders To rhesus-negative woman for prevention of Rh0(D) sensitisation, following any potentially sensitising episode (e.g. stillbirth, abortion, amniocentesis) after 20 weeks’ gestation ▶BY DEEP INTRAMUSCULAR INJECTION ▶Females of childbearing potential: 500 units per episode, dose to be administered immediately or within 72 hours, subcutaneous route used for patients with bleeding disorders To rhesus-negative woman for prevention of Rh0(D) sensitisation, antenatal prophylaxis ▶BY DEEP INTRAMUSCULAR INJECTION ▶Females of childbearing potential: 500 units, dose to be given at weeks 28 and 34 of pregnancy, if infant rhesus- positive, a further dose is still needed immediately or within 72 hours of delivery, subcutaneous route used for patients with bleeding disorders To rhesus-negative woman for prevention of Rh0(D) sensitisation, antenatal prophylaxis (alternative NICE recommendation) ▶BY DEEP INTRAMUSCULAR INJECTION ▶Females of childbearing potential: 1000–1650 units, dose to be given at weeks 28 and 34 of pregnancy, alternatively 1500 units for 1 dose, dose to be given between 28 and 30 weeks gestation To rhesus-negative woman for prevention of Rh0(D) sensitisation, following Rh0(D) incompatible blood transfusion ▶BY DEEP INTRAMUSCULAR INJECTION ▶Females of childbearing potential: 100–125 units per mL of transfused rhesus-positive red cells, subcutaneous route used for patients with bleeding disorders RHOPHYLAC ® To rhesus-negative woman for prevention of Rh0(D) sensitisation, following birth of rhesus-positive infant ▶BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION ▶Females of childbearing potential: 1000–1500 units, dose to administered immediately or within 72 hours; for large transplacental bleed, extra 100 units per mL fetal red cells (preferably by intravenous injection), intravenous route recommended for patients with bleeding disorders To rhesus-negative woman for prevention of Rh0(D) sensitisation, following any potentially sensitising episode (e.g. abortion, amniocentesis, chorionic villous sampling) up to 12 weeks’ gestation ▶BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION ▶Females of childbearing potential: 1000 units per episode, dose to be administered immediately or within 72 hours, intravenous route recommended for patients with bleeding disorders, higher doses may be required after 12 weeks gestation To rhesus-negative woman for prevention of Rh0(D) sensitisation, antenatal prophylaxis ▶BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION ▶Females of childbearing potential: 1500 units, dose to be given between weeks 28–30 of pregnancy; if infant rhesus-positive, a further dose is still needed immediately or within 72 hours of delivery, intravenous route recommended for patients with bleeding disorders To rhesus-negative woman for prevention of Rh0(D) sensitisation, following Rh0(D) incompatible blood transfusion ▶BY INTRAVENOUS INJECTION ▶Females of childbearing potential: 50 units per mL of transfused rhesus-positive blood, alternatively 100 units per of mL of erythrocyte concentrate, intravenous route recommended for patients with bleeding disorders
PDF page 1378